ProCE Banner Activity

PARP Inhibitor Combination Therapies: A New Horizon in Prostate Cancer Care

Slideset Download
Download these slides from a live symposium for the latest evidence on PARP inhibitor plus AR-targeting combination therapies for the treatment of metastatic castration-resistant prostate cancer.

Released: February 22, 2022

Expiration: February 21, 2023

Share

Faculty

Maha Hussain

Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Maha Hussain, MD, FACP, FASCO, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Novartis, Pfizer and Tempus and funds for research support paid to her institution from Arvinas, AstraZeneca, Bayer, and Genentech.